Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 7Lymphoma, B-Cell 5Lymphoma 3Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 9Magnetic Resonance Spectroscopy 8Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6polatuzumab vedotin 5obinutuzumab 5Biopsy 5zanubrutinib 4glofitamab 4Nivolumab 4Etoposide 4Dexamethasone 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Leukapheresis 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2loncastuximab tesirine 2etoposide phosphate 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × polatuzumab vedotin × 90 days × Clear all
NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Celgene

Phase 1 Recruiting
224 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

Phase 1/2 Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07502872 2026-03-31

TPG

Brown University

Phase 2 Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡